MA27812A1 - Utilisation d'un inhibiteur de tyrosine kinase c-abl, pdgf-r ou c-kit dans le traitement du diabete - Google Patents

Utilisation d'un inhibiteur de tyrosine kinase c-abl, pdgf-r ou c-kit dans le traitement du diabete

Info

Publication number
MA27812A1
MA27812A1 MA28624A MA28624A MA27812A1 MA 27812 A1 MA27812 A1 MA 27812A1 MA 28624 A MA28624 A MA 28624A MA 28624 A MA28624 A MA 28624A MA 27812 A1 MA27812 A1 MA 27812A1
Authority
MA
Morocco
Prior art keywords
diabetes
pdgf
kit
treatment
tyrosine kinase
Prior art date
Application number
MA28624A
Other languages
English (en)
Inventor
Robert Pers Haegerkvist
Nils Richard Welsh
Original Assignee
Haegerkvist Robert Per
Nils Richard Welsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312086A external-priority patent/GB0312086D0/en
Priority claimed from GB0402682A external-priority patent/GB0402682D0/en
Application filed by Haegerkvist Robert Per, Nils Richard Welsh filed Critical Haegerkvist Robert Per
Publication of MA27812A1 publication Critical patent/MA27812A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur l'utilisation d'un inhibiteur de tyrosine kinase c-Abl-. PDGF-R- ou c-kit-, tel que 4-(4-méthylpipérazin-1-ylméthyl)-N-[4-méthyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phényl]-benzamide, ou des sels de celui-ci acceptables d'un point de vue pharmaceutique dans la fabrication d'un médicament destiné à être utilisé dans le traitement du diabète, comme le diabète de type I et le diabète de type II
MA28624A 2003-05-27 2005-11-24 Utilisation d'un inhibiteur de tyrosine kinase c-abl, pdgf-r ou c-kit dans le traitement du diabete MA27812A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312086A GB0312086D0 (en) 2003-05-27 2003-05-27 Organic compounds
GB0402682A GB0402682D0 (en) 2004-02-06 2004-02-06 Organic compounds

Publications (1)

Publication Number Publication Date
MA27812A1 true MA27812A1 (fr) 2006-03-01

Family

ID=33492240

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28624A MA27812A1 (fr) 2003-05-27 2005-11-24 Utilisation d'un inhibiteur de tyrosine kinase c-abl, pdgf-r ou c-kit dans le traitement du diabete

Country Status (21)

Country Link
US (1) US7875616B2 (fr)
EP (1) EP1631291B1 (fr)
JP (1) JP4776537B2 (fr)
KR (1) KR101102229B1 (fr)
AT (1) ATE439133T1 (fr)
BR (1) BRPI0410704A (fr)
CA (1) CA2526594C (fr)
DE (1) DE602004022540D1 (fr)
DK (1) DK1631291T3 (fr)
ES (1) ES2331800T3 (fr)
HK (1) HK1087638A1 (fr)
IL (1) IL171927A (fr)
IS (1) IS2712B (fr)
MA (1) MA27812A1 (fr)
MX (1) MXPA05012739A (fr)
NO (1) NO331715B1 (fr)
NZ (1) NZ543709A (fr)
PL (1) PL1631291T3 (fr)
PT (1) PT1631291E (fr)
RU (1) RU2365373C2 (fr)
WO (1) WO2004105763A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502809A (ja) * 2003-08-15 2007-02-15 アブ サイエンス ＩＩ型糖尿病を治療するためのｃ−ｋｉｔ阻害剤の使用方法
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
US20120329794A1 (en) * 2006-06-30 2012-12-27 Kyowa Hakko Kirin Co., Ltd. Ab1 KINASE INHIBITORS
BR112014005653A2 (pt) * 2011-09-15 2017-03-28 Novartis Ag uso de 4-amino-5-fluoro-3[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-1l]1h-quinolin-ona no tratamento de câncer de em pacientes com insuficiência hepática moderada

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (fr) * 1992-04-03 1994-06-21 Ciba Geigy Ag
EP0773313B1 (fr) * 1995-10-11 2000-08-09 ARTEVA TECHNOLOGIES S.à.r.l. Ceintures de sécurité résistants à la flamme contenant des fibres de polyester modifiées par du phosphore
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
ES2234523T3 (es) * 1999-03-01 2005-07-01 Pfizer Products Inc. Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos.
AU2001234943A1 (en) * 2000-02-15 2001-08-27 Teva Pharmaceutical Industries Ltd. A method for synthesizing leflunomide
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
TWI270545B (en) * 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
PE20020776A1 (es) * 2000-12-20 2002-08-22 Sugen Inc Indolinonas 4-aril sustituidas
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AUPS243002A0 (en) 2002-05-20 2002-06-13 Baker Medical Research Institute Therapeutic target and uses thereof
DE10235227A1 (de) * 2002-08-01 2004-02-19 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes
EP1576129A4 (fr) * 2002-08-09 2008-01-23 Theravance Inc Polypeptides de fusion d'oncokinase associes a des troubles hyperproliferatifs, acides nucleiques codant pour lesdits polypeptides et leurs methodes de detection et d'identification
WO2004043408A2 (fr) * 2002-11-13 2004-05-27 Genpath Pharmaceuticals, Incorporated Gpc15 : methodes et compositions pour le traitement du cancer
DE10255360A1 (de) * 2002-11-27 2004-06-17 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes

Also Published As

Publication number Publication date
EP1631291B1 (fr) 2009-08-12
DK1631291T3 (da) 2009-11-02
IL171927A0 (en) 2006-04-10
EP1631291A2 (fr) 2006-03-08
NO331715B1 (no) 2012-03-05
US20070072932A1 (en) 2007-03-29
ES2331800T3 (es) 2010-01-15
IS2712B (is) 2011-01-15
IS8139A (is) 2005-11-22
CA2526594C (fr) 2011-11-08
ATE439133T1 (de) 2009-08-15
NO20056188L (no) 2005-12-23
WO2004105763A2 (fr) 2004-12-09
PL1631291T3 (pl) 2010-04-30
KR101102229B1 (ko) 2012-01-05
JP4776537B2 (ja) 2011-09-21
HK1087638A1 (en) 2006-10-20
NZ543709A (en) 2009-04-30
AU2004243491A1 (en) 2004-12-09
BRPI0410704A (pt) 2006-06-13
PT1631291E (pt) 2009-10-28
RU2365373C2 (ru) 2009-08-27
CA2526594A1 (fr) 2004-12-09
WO2004105763A3 (fr) 2005-06-02
MXPA05012739A (es) 2006-05-17
IL171927A (en) 2011-10-31
JP2006528225A (ja) 2006-12-14
RU2005140516A (ru) 2007-07-10
DE602004022540D1 (de) 2009-09-24
KR20060021865A (ko) 2006-03-08
US7875616B2 (en) 2011-01-25

Similar Documents

Publication Publication Date Title
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
MA27812A1 (fr) Utilisation d'un inhibiteur de tyrosine kinase c-abl, pdgf-r ou c-kit dans le traitement du diabete
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
NO20043585L (no) Behandling av reumatoid artritt
ATE468855T1 (de) Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
ATE492277T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms
TNSN05304A1 (en) Use of tyrosine kinase inhibitor to treat diabetes
DE60311284D1 (de) 4-(3,5-dicyanophenoxy)pyrazol-derivate zur verwendung als reverse transkriptase modulatoren zur behandlung von u.a. hiv
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
DE60111044D1 (de) Verwendung von aminen